TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ADAP Stock 12 Month Forecast
There Are No Analyst Ratings for ADAP In The Last 3 Months.
Highest Price Target―
Average Price Target―
Lowest Price Target―
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
ADAP Financial Forecast
ADAP Earnings Forecast
Next quarter’s earnings estimate for ADAP is -$0.12 with a range of -$0.12 to -$0.12. The previous quarter’s EPS was -$0.02. ADAP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ADAP has Performed in-line its overall industry.
Next quarter’s earnings estimate for ADAP is -$0.12 with a range of -$0.12 to -$0.12. The previous quarter’s EPS was -$0.02. ADAP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ADAP has Performed in-line its overall industry.
ADAP Sales Forecast
Next quarter’s sales forecast for ADAP is $4.85M with a range of $0.00 to $9.70M. The previous quarter’s sales results were $13.84M. ADAP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ADAP has Performed in-line its overall industry.
Next quarter’s sales forecast for ADAP is $4.85M with a range of $0.00 to $9.70M. The previous quarter’s sales results were $13.84M. ADAP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ADAP has Performed in-line its overall industry.
H.C. Wainwright downgrades Adaptimmune Therapeutics (ADAP) to a HoldValuation and Risks. We lower our rating on ADAP to a price target due to the lack of meaningful near-term catalysts. Risks: (1) clinical, (2) regulatory, (3) commercial, (4) competition, (5) dilution and (6) delisting.
H.C. Wainwright downgrades Adaptimmune Therapeutics (ADAP) to a HoldValuation and Risks. We lower our rating on ADAP to a price target due to the lack of meaningful near-term catalysts. Risks: (1) clinical, (2) regulatory, (3) commercial, (4) competition, (5) dilution and (6) delisting.
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +5.47% per trade.
trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of -2.73% per trade.
Copying Peter Lawson's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +21.79% per trade.
trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +35.72% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ADAP Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
3
2
0
0
0
Buy
0
0
0
0
0
Hold
13
20
20
19
15
Sell
1
1
1
1
1
Strong Sell
0
0
4
6
8
total
17
23
25
26
24
In the current month, ADAP has received 0Buy Ratings, 15Hold Ratings, and 9Sell Ratings. ADAP average Analyst price target in the past 3 months is ―.
Each month's total comprises the sum of three months' worth of ratings.
ADAP Stock Forecast FAQ
What is ADAP’s average 12-month price target, according to analysts?
Currently, no data Available
What is ADAP’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for ADAP, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ADAP a Buy, Sell or Hold?
Currently, no data Available
What is Adaptimmune Therapeutics Plc.’s price target?
Currently, no data Available
What do analysts say about Adaptimmune Therapeutics Plc.?
Not enough analysts have published a price target to provide an average price target.
How can I buy shares of ADAP?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.